Drug Trial Radar · NCT07775404
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
351
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Apr 6, 2028
Study completion Apr 13, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.
Conditions
- Obesity
- Overweight
Interventions
ElecoglipronDrug
Elecoglipron film coated tablet once daily
PlaceboDrug
Placebo matching elecoglipron film-coated tablet once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline to Week 52 in body weightTime frame: Week 52
- Participants achieving at least 5% body weight loss at Week 52Time frame: Week 52
Locations
49 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Baotou, China · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Changde, China · Recruiting
Research Site
Changsha, China · Recruiting
Research Site
Changzhou, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Huangshi, China · Recruiting
Research Site
Jincheng, China · Recruiting
Research Site
Jinzhou Shi, China · Not yet recruiting
Research Site
Langfang, China · Recruiting
Research Site
Luoyang, China · Not yet recruiting
Research Site
Meihekou, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Nanyang, China · Recruiting
Research Site
Nanyang, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Shantou, China · Recruiting
Research Site
Shenyang, China · Recruiting
Research Site
Shenyang, China · Recruiting
Research Site
Shijiazhuang, China · Recruiting
Research Site
Wuhan, China · Withdrawn
Research Site
Wuhu, China · Recruiting
Research Site
Xianyang, China · Recruiting
Research Site
Xuzhou, China · Recruiting
Research Site
Yan’an, China · Recruiting
Research Site
Yueyang, China · Recruiting
Research Site
Zhumadian, China · Recruiting
Research Site
Zibo, China · Recruiting
Research Site
Hong Kong, Hong Kong · Recruiting
Research Site
Shatin, Hong Kong, Hong Kong · Recruiting
Research Site
Alor Star, Malaysia · Recruiting
Research Site
Kuala Lumpur, Malaysia · Recruiting
Research Site
Kuching, Malaysia · Recruiting
Research Site
Putrajaya, Malaysia · Recruiting
Research Site
Sarawak Miri, Malaysia · Recruiting
Research Site
Seremban, Malaysia · Not yet recruiting
Research Site
Seri Manjung, Malaysia · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.